In the first half of the year, China's 38 “new global” innovative drugs were approved. Meanwhile, in the first half of this year, the total amount of foreign authorized transactions for innovative drugs in China was about 110 billion US dollars, reaching 80% of the total for the full year of 2025, a record high for the same period in history. From the approval for the launch of the world's first solid tumor CAR-T cell drug to a record high overseas authorized transaction volume for innovative drugs in the same period, China's innovative drugs are entering a new stage of development. According to the data, by the end of June, the State Drug Administration had approved 2,318 drug marketing registration applications this year, including 38 “new global” innovative drugs. In the first half of this year, the total amount of foreign authorized transactions for innovative drugs in China was about 110 billion US dollars, reaching 80% of the total for the full year of 2025. From “following” to “running side by side”, from individual products to the capabilities of the entire industry chain, China's innovative drugs are moving at an accelerated pace to the world. Moving an innovative drug from the laboratory to the market requires not only innovation at the source, but also large-scale, low-cost manufacturing capabilities. Today, artificial intelligence is deeply embedded in drug development processes. At the Shanghai National Key Laboratory for Neurological and Oncology Drug Development, from target discovery and molecular design to activity prediction and toxicological evaluation, AI is helping developers reduce trial and error costs. According to the company's R&D personnel, it used to take about 10 days to generate 1,000 small molecules, but now with the AI-assisted drug design platform, it only takes about 2 minutes, and the screening efficiency is nearly 30 times higher. If laboratory innovation is the source of the birth of new drugs, then large-scale, low-cost manufacturing is the “last mile” of innovative drugs benefiting patients. As industry insiders say, China's innovative medicine is moving from a follower of global innovation to a co-builder who can work side by side with the world's top pharmaceutical companies.

In the first half of the year, China's 38 “new global” innovative drugs were approved. Meanwhile, in the first half of this year, the total amount of foreign authorized transactions for innovative drugs in China was about 110 billion US dollars, reaching 80% of the total for the full year of 2025, a record high for the same period in history. From the approval for the launch of the world's first solid tumor CAR-T cell drug to a record high overseas authorized transaction volume for innovative drugs in the same period, China's innovative drugs are entering a new stage of development. According to the data, by the end of June, the State Drug Administration had approved 2,318 drug marketing registration applications this year, including 38 “new global” innovative drugs. In the first half of this year, the total amount of foreign authorized transactions for innovative drugs in China was about 110 billion US dollars, reaching 80% of the total for the full year of 2025. From “following” to “running side by side”, from individual products to the capabilities of the entire industry chain, China's innovative drugs are moving at an accelerated pace to the world. Moving an innovative drug from the laboratory to the market requires not only innovation at the source, but also large-scale, low-cost manufacturing capabilities. Today, artificial intelligence is deeply embedded in drug development processes. At the Shanghai National Key Laboratory for Neurological and Oncology Drug Development, from target discovery and molecular design to activity prediction and toxicological evaluation, AI is helping developers reduce trial and error costs. According to the company's R&D personnel, in the past, it took about 10 days to generate 1,000 small molecules, but now with the AI-assisted drug design platform, it only takes about 2 minutes, and the screening efficiency is nearly 30 times higher. If laboratory innovation is the source of the birth of new drugs, then large-scale, low-cost manufacturing is the “last mile” of innovative drugs benefiting patients. As industry insiders say, China's innovative medicine is moving from a follower of global innovation to a co-builder who can work side by side with the world's top pharmaceutical companies.